Date |
Product |
Disease |
Phase |
Company |
Therapeutic area |
2016-09-08
|
Yeliva™ (ABC294640) |
refractory or relapsed multiple myeloma |
1b/2 |
Redhill Biopharma (Israel) |
Cancer - Oncology |
2016-09-07
|
AsiDNA™ |
|
preclinical |
Onxeo (France) |
Cancer - Oncology |
2016-09-07
|
PQ912 |
|
preclinical |
Probiodrug (Germany) |
Inflammatory diseases |
2016-09-07
|
combination of Diamyd®, vitamin D and etanercept |
type 1 diabetes |
2 |
Diamyd Medical (Sweden) |
Metabolic diseases |
2016-09-07
|
Diamyd® diabetes vaccine |
type 1 diabetes |
2 |
Diamyd Medical (Sweden) |
Metabolic diseases |
2016-09-06
|
combination of fluticasone furoate, umeclidinium and vilanterol (FF/UMEC/VI) |
chronic obstructive pulmonary disease (COPD) |
3 |
GSK (UK) Theravance, now Innoviva (USA - CA) |
Inflammatory diseases - Respiratory diseases |
2016-09-02
|
MD1003 (high doses of pharmaceutical-grade biotin) |
multiple sclerosis |
3 |
Medday (France) |
Autoimmune diseases - Neurodegenerative diseases |
2016-08-31
|
AST-OPC1 (oligodendrocyte progenitor cells) |
spinal cord injury |
1-2a |
Asterias Biotherapeutics (USA -CA) |
Rare diseases - Regenerative medicine |
2016-08-30
|
TK216 - small molecule Ewing Sarcoma breakpoint region 1/Friend leukemia virus integration 1 fusion protein inhibitor |
Ewing sarcoma |
1 |
Oncternal Therapeutics (USA - CA) |
Cancer - Oncology - Rare diseases |
2016-08-30
|
ARRY-797 |
lamin A/C-related dilated cardiomyopathy |
2 |
Array BioPharma (USA - CO) |
Cardiovascular diseases - Rare diseases |
2016-08-30
|
tarextumab (anti-Notch2/3, OMP-59R5) |
small cell lung cancer |
1b/2 |
OncoMed Pharmaceuticals (USA - CA) GSK (UK) |
Cancer - Oncology |
2016-08-29
|
Prolia® (denosumab) |
glucocorticoid-induced osteoporosis |
3 |
Amgen (USA - CA) |
Bone diseases |
2016-08-29
|
Praluent® (alirocumab - SAR236553/REGN727) |
heterozygous familial hypercholesterolemia (HeFH) |
3 |
Sanofi (France) Regeneron Pharmaceuticals (USA - NY) |
Cardiovascular diseases - Genetic diseases - Rare diseases |
2016-08-29
|
Xarelto® (rivaroxaban) |
non-valvular atrial fibrillation |
post-authorisation observational |
Bayer Healthcare (Germany) |
Cardiovascular diseases |
2016-08-25
|
solithromycin |
community-acquired bacterial pneumonia (CABP) |
3 |
Cempra (USA - NC) |
Infectious diseases |
2016-08-25
|
daratumumab combined with bortezomib and dexamethasone |
relapsed or refractory multiple myeloma |
3 |
Janssen Biotech - J&J (USA) Genmab (Denmark) |
Cancer - Oncology |
2016-08-25
|
BioChaperone® PDGF-BB (Platelet Derived Growth factor) |
diabetic foot ulcer |
3 |
Adocia (France) |
Metabolic diseases - Cardiovascular diseases |
2016-08-25
|
Qinprezo™ (vosaroxin) |
acute myeloid leukemia |
|
Sunesis Pharmaceuticals (USA - CA) |
Cancer - Oncology |
2016-08-24
|
edoxaban |
non-valvular atrial fibrillation |
3 |
Daiichi Sankyo (Japan) |
Cardiovascular diseases |
2016-08-22
|
GLPG0634 (filgotinib) |
rheumatoid arthritis |
3 |
Gilead Sciences (USA - CA) Galapagos (Belgium) |
Autoimmune diseases – Inflammatory diseases - Rheumatic diseases |